These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 19708820

  • 1. Antigen-specific therapies in multiple sclerosis.
    Giacomini PS, Bar-Or A.
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):551-60. PubMed ID: 19708820
    [Abstract] [Full Text] [Related]

  • 2. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B, Hartung HP.
    Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020
    [Abstract] [Full Text] [Related]

  • 3. Antigen-specific therapies in MS - Current concepts and novel approaches.
    Lutterotti A, Sospedra M, Martin R.
    J Neurol Sci; 2008 Nov 15; 274(1-2):18-22. PubMed ID: 18599087
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Current concepts of the cellular and molecular pathophysiology of multiple sclerosis.
    Greenstein JI.
    Dev Neurobiol; 2007 Aug 15; 67(9):1248-65. PubMed ID: 17514718
    [Abstract] [Full Text] [Related]

  • 7. Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary.
    Lopez-Diego RS, Weiner HL.
    Nat Rev Drug Discov; 2008 Nov 15; 7(11):909-25. PubMed ID: 18974749
    [Abstract] [Full Text] [Related]

  • 8. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.
    Wiendl H, Hohlfeld R.
    Neurology; 2009 Mar 17; 72(11):1008-15. PubMed ID: 19289741
    [Abstract] [Full Text] [Related]

  • 9. Future research directions in multiple sclerosis therapies.
    Greenberg BM, Calabresi PA.
    Semin Neurol; 2008 Feb 17; 28(1):121-7. PubMed ID: 18256992
    [Abstract] [Full Text] [Related]

  • 10. Development of biomarkers in multiple sclerosis.
    Bielekova B, Martin R.
    Brain; 2004 Jul 17; 127(Pt 7):1463-78. PubMed ID: 15180926
    [Abstract] [Full Text] [Related]

  • 11. Early treatment of multiple sclerosis to prevent neurologic damage.
    Coyle PK.
    Neurology; 2008 Dec 09; 71(24 Suppl 3):S3-7. PubMed ID: 19064872
    [Abstract] [Full Text] [Related]

  • 12. Myelin peptides in multiple sclerosis.
    Grau-López L, Raïch D, Ramo-Tello C, Naranjo-Gómez M, Dàvalos A, Pujol-Borrell R, Borràs FE, Martínez-Cáceres E.
    Autoimmun Rev; 2009 Jul 09; 8(8):650-3. PubMed ID: 19393199
    [Abstract] [Full Text] [Related]

  • 13. The development of stroke therapeutics: promising mechanisms and translational challenges.
    Zaleska MM, Mercado ML, Chavez J, Feuerstein GZ, Pangalos MN, Wood A.
    Neuropharmacology; 2009 Feb 09; 56(2):329-41. PubMed ID: 19007799
    [Abstract] [Full Text] [Related]

  • 14. Contribution of peptides to multiple sclerosis research.
    Alcaro MC, Papini AM.
    Biopolymers; 2006 Feb 09; 84(4):349-67. PubMed ID: 16518843
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Profiling the autoantibody repertoire by serological antigen selection.
    Somers V, Govarts C, Hellings N, Hupperts R, Stinissen P.
    J Autoimmun; 2005 Nov 09; 25(3):223-8. PubMed ID: 16256306
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.